Managing irAEs is a Dynamic Discussion

In this special edition podcast, we spoke with both a physician and a nurse about the management of immune-related adverse events in patients with melanoma.

In recent years, immunotherapy agents have shown amazing success in treating patients with melanoma. For this special-edition podcast, we teamed up with our sister publication, Oncology Live, to bring the viewpoints of 2 melanoma experts on the importance of multidisciplinary care when managing immune-related adverse events (irAEs).

You’ll hear from Grace Cherry, NP, of UCLA’s Melanoma Program, and Omid Hamid, MD, chief of research, immune-oncology and co-director of the cutaneous malignancy program at the Angeles Clinic and Research Institute. They discuss their team approach to handling irAEs, as well as offer tips on establishing an open line of patient and provider communication to ensure that toxicities are reported — and handled – in a timely manner.

Related Videos
Reanne Booker on Factors to Consider When Discussing Palliative Radiation
Mehra Details the Importance of PD-L1 Expression in HNSCC Treatment Selection
Ahulwalia on Targeting the Blood Brain Barrier With Novel Immunotherapies and Precision Oncology
Verina on Tackling Neurological Toxicities From CAR T-Cell Therapy
Sherry Adkins Talks Primary Care Provider Communication Following CAR T-cell Therapy
Paula Anastasia on PARP Inhibitor Ineligibility Factors for Women With Ovarian Cancer
Beth Sandy on Incorporating Amivantamab and Mobocertinib into Clinical Practice for Patients With EGFR Exon 20 Insertion NSCLC
Kelley Rone on the Evolving Role of Immunotherapy in GI Cancers
Related Content
© 2023 MJH Life Sciences

All rights reserved.